Controversial GM seeds fuel earnings but Wall Street remains cautious.
|
Nonprofit SRI International gets funds to help figure out which counter-terrorism drug candidates should move on to clinical trials.
|
Convincing U.S. venture capitalists to put cash into stem cell startups is a very tough task.
|
New tool aims to link diseases with treatments.
|
'Immunodrug' tricks the immune system.
|
Changing tack on one problem could help solve others.
|
The world is looking for a pandemic strain of flu, but not hard enough.
|
Mature companies are still heading west for funding.
|
Researchers hope big pharma will get on board to develop a microbicide for women.
|
Red Herring magazine’s top private European bioscience companies for 2006.
|
A study claims Celebrex should not receive preferential treatment over Vioxx.
|
High-tech firms raised $336 million in the third quarter, down 23 percent from the year-ago quarter.
|
A French think tank wants to build a tech research hub to rival MIT and Oxford.
|
Oculus Innovative Sciences puts water to work for the healthcare industry.
|
Caris becomes the majority shareholder in Pathology Partners, investing $120 million to recapitalize it.
|